Viking Therapeutics Inc
VKTXHealthcare|Biotechnology|USA
$38.86
-2.28 (-5.54%)
Tangible Book
$4.33
Financials
Financial Snapshot
Market Cap
$4.51B
Enterprise Value
$602.8M
Revenue (TTM)
$0.00
Net Income (TTM)
$-472.3M
Cash & Equivalents
—
Net Cash/Share
$4.29
Free Cash Flow (TTM)
$-340.3M
Operating CF (TTM)
$-340.3M
Debt/Equity
0
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$85.1M
Monthly Burn
$28.4M
Est. Runway
—
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $13.2M | $20.6M | $301.5M | $275.6M | $248.4M | $202.1M | $155.5M | $362.1M | $902.6M | $705.7M | $603.0M | |
| Operating Cash Flow | $-11.1M | $-14.8M | $-18.8M | $-24.8M | $-21.8M | $-47.6M | $-48.4M | $-73.4M | $-87.8M | $-278.7M | $-340.3M | |
| Free Cash Flow | $-11.1M | $-14.8M | $-18.8M | $-24.8M | $-21.8M | $-47.6M | $-48.4M | $-73.4M | $-87.8M | $-278.7M | $-340.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $10.3M | $22.4M | $300.3M | $887.0K | $950.0K | $6.9M | $4.2M | $271.4M | $612.5M | $76.4M | $88.2M |
R&D Spending
R&D (TTM)
$453.7M
R&D Intensity
—
R&D Growth YoY
+31.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $9.0M | $13.7M | $19.0M | $23.6M | $31.9M | $45.0M | $54.2M | $63.8M | $101.6M | $345.0M | $453.7M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | — | — | |
| SG&A | $4.8M | $5.3M | $7.1M | $9.1M | $10.7M | $10.7M | $16.1M | $37.0M | $49.3M | $48.4M | $48.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $9.0M | $13.7M | $19.0M | $23.6M | $31.9M | $45.0M | $54.2M | $63.8M | $101.6M | $345.0M | $453.7M | |
| SG&A | $4.8M | $5.3M | $7.1M | $9.1M | $10.7M | $10.7M | $16.1M | $37.0M | $49.3M | $48.4M | $48.3M | |
| Operating Income | $-13.8M | $-19.1M | $-26.2M | $-32.7M | $-42.7M | $-55.7M | $-70.4M | $-100.8M | $-150.9M | $-393.3M | $-502.0M | |
| Interest Expense | $-1.8M | $-1.3M | $-404.0K | $-146.0K | $-106.0K | $-18.0K | $-59.0K | $-88.0K | $-94.0K | $-56.0K | $-32.0K | |
| Pretax Income | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | $-472.3M | |
| Net Income | $-14.7M | $-20.6M | $-22.1M | $-25.8M | $-39.5M | $-55.0M | $-68.9M | $-85.9M | $-110.0M | $-359.6M | $-472.3M | |
| EPS (Diluted) | -0.90 | -0.79 | -0.38 | -0.36 | -0.54 | -0.71 | -0.90 | -0.91 | -1.01 | -3.19 | -4.14 | |
| EBITDA | $-12.9M | $-19.3M | $-21.7M | $-32.4M | $-42.4M | $-55.4M | $-70.1M | $-100.5M | $-150.6M | $-392.9M | $-501.6M | |
| Shares Out. (M) | 16.28 | 25.98 | 57.58 | 71.96 | 72.60 | 77.20 | 76.83 | 94.35 | 109.04 | 112.67 | 115.57 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1M | $9.0M | $24.8M | $8.4M | $29.1M | $26.4M | $36.6M | $55.5M | $26.7M | $165.8M | $118.1M | |
| Marketable Securities | $10.1M | $11.6M | $276.7M | $267.3M | $219.3M | $175.7M | $118.9M | $306.6M | $875.9M | $539.9M | $484.8M | |
| Total Current Assets | $14.0M | $21.9M | $302.1M | $283.5M | $256.1M | $210.5M | $167.0M | $367.2M | $907.2M | $715.6M | $608.2M | |
| Total Assets | $14.5M | $22.1M | $302.3M | $284.3M | $256.5M | $210.7M | $168.5M | $368.5M | $908.3M | $715.7M | $608.2M | |
| Total Current Liabilities | $6.5M | $8.7M | $4.5M | $6.8M | $12.1M | $8.8M | $21.9M | $19.1M | $27.4M | $76.7M | $106.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.5M | $8.7M | $4.6M | $7.1M | $12.2M | $8.8M | $23.2M | $20.1M | $28.0M | $76.7M | $106.3M | |
| Stockholders' Equity | $8.0M | $13.5M | $297.8M | $277.1M | $244.3M | $201.9M | $145.3M | $348.4M | $880.3M | $639.1M | $501.9M | |
| Retained Earnings | $-60.3M | $-80.9M | $-102.9M | $-128.7M | $-168.2M | $-223.2M | $-292.0M | $-377.9M | $-487.9M | $-847.5M | $-1.01B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-11.1M | $-14.8M | $-18.8M | $-24.8M | $-21.8M | $-47.6M | $-48.4M | $-73.4M | $-87.8M | $-278.7M | $-340.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | $-11.1M | $-14.8M | $-18.8M | $-24.8M | $-21.8M | $-47.6M | $-48.4M | $-73.4M | $-87.8M | $-278.7M | $-340.3M | |
| Investing Cash Flow | $3.0M | $-1.7M | $-265.7M | $7.5M | $41.6M | $38.0M | $54.8M | $-179.1M | $-553.4M | $341.4M | $332.3M | |
| Financing Cash Flow | $10.3M | $22.4M | $300.3M | $887.0K | $950.0K | $6.9M | $4.2M | $271.4M | $612.5M | $76.4M | $88.2M | |
| Issuance of Stock | $11.5M | $22.4M | $296.6M | $0.00 | $0.00 | $0.00 | $0.00 | $269.8M | $597.1M | $0.00 | $11.6M | |
| Repurchase of Stock | $-1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-6.8M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-95.0K | $-77.0K | $-3.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.8M | $1.5M | $2.6M | $3.7M | $5.8M | $6.1M | $8.7M | $16.8M | $29.7M | $40.8M | $39.8M | |
| Net Change in Cash | $2.3M | $5.9M | $15.8M | $-16.4M | $20.7M | $-2.7M | $10.3M | $18.9M | $-28.8M | $139.1M | $80.2M |
Dilution Tracker
Shares outstanding grew 49.7% over 5 years — significant dilution
Shares Outstanding
116M
5-Year Share Growth
+49.7%
Stock Issuance (TTM)
$11.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 16.28 | 25.98 | 57.58 | 71.96 | 72.60 | 77.20 | 76.83 | 94.35 | 109.04 | 112.67 | 115.57 | |
| YoY Change % | — | 59.6% | 121.6% | 25.0% | 0.9% | 6.3% | -0.5% | 22.8% | 15.6% | 3.3% | 2.6% | |
| Stock Issuance | $11.5M | $22.4M | $296.6M | $0.00 | $0.00 | $0.00 | $0.00 | $269.8M | $597.1M | $0.00 | $11.6M | |
| Stock Repurchase | $-1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-6.8M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.8M | $1.5M | $2.6M | $3.7M | $5.8M | $6.1M | $8.7M | $16.8M | $29.7M | $40.8M | $39.8M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | -175.7% | -191.4% | -14.2% | -9.0% | -15.1% | -24.6% | -39.7% | -34.8% | -17.9% | -47.3% | -67.5% | |
| ROA % | -98.3% | -112.3% | -13.6% | -8.8% | -14.6% | -23.5% | -36.3% | -32.0% | -17.2% | -44.3% | -62.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S—
Historical— / — / —
Industry Med.9.51
P/B8.97
Historical— / — / 8.97
Industry Med.2.93
EV/EBITDA-7.59
Historical-7.59 / — / —
Industry Med.13.14
EV/Revenue—
Historical— / — / —
Industry Med.8.71
P/FCF—
Historical— / — / —
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$4.33
Net Current Assets
$4.330
Net-Net Working Capital
$4.29
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 3.08 | 10.80 | 1.84 | 2.10 | 1.69 | 1.78 | 5.06 | 5.35 | 5.10 | 6.32 | 8.97 | |
| EV/EBITDA | -1.15 | -6.65 | -11.42 | -9.43 | -3.87 | -2.85 | -8.30 | -14.94 | -23.83 | -8.48 | -7.59 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $157.85M |
| Net Income | $-563.91M | $-592.95M | $-522.15M |
| EPS | -4.78 | -4.76 | -3.95 |
| Book Value per Share | 3.58 | 5.92 | 1.46 |
| Operating Cash Flow per Share | -4.51 | -3.70 | 0.00 |
| Operating CF | $-521.21M | $-427.60M | $0.00M |